Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

dButterz Nov. 15 at 3:28 AM

$GRI this was 9/15/25 listen what ceo Mark says from 5:30 to 5:45 during conference call. https://journey.ct.events/view/6e657d44-8f9f-4d19-a306-6580fbcb1031

0 · Reply

mendez628 Nov. 15 at 12:10 AM

$GRI gotta be honest, I expected this to absolutely bomb with those booty ass earnings, but I’m pretty impressed of how well it held up

1 · Reply

NolAsrtormZ Nov. 14 at 9:44 PM

$GRI.... Drw securities is not a hedge fund. They are here 4 the Data gamble

0 · Reply

LuckyRing Nov. 14 at 9:40 PM

$GRI Management owns less than 1 percent of the stock - confidence is way down! All they have done is suck money out with their overpriced salaries.

1 · Reply

NolAsrtormZ Nov. 14 at 9:18 PM

$AVXL bring your bags to $GRI bio we have iPf data by end of November 🤑😇🤪 Data chasers, whats another gamble

0 · Reply

nothximgood Nov. 14 at 9:14 PM

$GRI The good news is all trial participants no longer have IPF. The bad news is they are all dead.

1 · Reply

mendez628 Nov. 14 at 8:54 PM

$GRI did surprisingly well despite booty earnings

0 · Reply

NolAsrtormZ Nov. 14 at 8:40 PM

$GRI

0 · Reply

NolAsrtormZ Nov. 14 at 8:38 PM

$GRI This is a big deal.... you go from about 25,000 institutions shares 2 over 138,000 institutional shares

0 · Reply

NolAsrtormZ Nov. 14 at 8:36 PM

$GRI man oh man, what nice buy

0 · Reply

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Aug 14, 2025, 9:15 AM EDT - 3 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 3 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 22, 2025, 8:45 AM EDT - 4 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:45 AM EDT - 4 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 5 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 9:15 AM EDT - 6 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 16, 2025, 9:15 AM EDT - 6 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 15, 2025, 8:35 AM EDT - 6 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 8, 2025, 8:45 AM EDT - 6 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 6 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 7 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 8 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 8 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:07 AM EDT - 8 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Mar 31, 2025, 8:00 AM EDT - 8 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 18, 2025, 9:05 AM EDT - 8 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 8 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 11, 2025, 8:35 AM EDT - 8 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 4:05 PM EST - 9 months ago

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 9:00 AM EST - 9 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 23, 2024, 9:00 AM EST - 11 months ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Apr 8, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Apr 1, 2024, 7:35 AM EDT - 1 year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

dButterz Nov. 15 at 3:28 AM

$GRI this was 9/15/25 listen what ceo Mark says from 5:30 to 5:45 during conference call. https://journey.ct.events/view/6e657d44-8f9f-4d19-a306-6580fbcb1031

0 · Reply

mendez628 Nov. 15 at 12:10 AM

$GRI gotta be honest, I expected this to absolutely bomb with those booty ass earnings, but I’m pretty impressed of how well it held up

1 · Reply

NolAsrtormZ Nov. 14 at 9:44 PM

$GRI.... Drw securities is not a hedge fund. They are here 4 the Data gamble

0 · Reply

LuckyRing Nov. 14 at 9:40 PM

$GRI Management owns less than 1 percent of the stock - confidence is way down! All they have done is suck money out with their overpriced salaries.

1 · Reply

NolAsrtormZ Nov. 14 at 9:18 PM

$AVXL bring your bags to $GRI bio we have iPf data by end of November 🤑😇🤪 Data chasers, whats another gamble

0 · Reply

nothximgood Nov. 14 at 9:14 PM

$GRI The good news is all trial participants no longer have IPF. The bad news is they are all dead.

1 · Reply

mendez628 Nov. 14 at 8:54 PM

$GRI did surprisingly well despite booty earnings

0 · Reply

NolAsrtormZ Nov. 14 at 8:40 PM

$GRI

0 · Reply

NolAsrtormZ Nov. 14 at 8:38 PM

$GRI This is a big deal.... you go from about 25,000 institutions shares 2 over 138,000 institutional shares

0 · Reply

NolAsrtormZ Nov. 14 at 8:36 PM

$GRI man oh man, what nice buy

0 · Reply

NolAsrtormZ Nov. 14 at 8:34 PM

$GRI 100,000 share buyer🤑🤑👀👀

0 · Reply

NolAsrtormZ Nov. 14 at 5:35 PM

$GRI They raised cash because they r greedy management lol They only had cash until 3rd quarter Management needs Christmas 🎄 bonuses

1 · Reply

LuckyRing Nov. 14 at 4:18 PM

$GRI Delay because waiting of FDA approval? Shut downs?

0 · Reply

Ataifanboymentalhealthz Nov. 14 at 3:55 PM

$GRI everyone freaking out is funny they don’t know timelines. Last 6 week interim data was positive and delayed by 6 months or more.

0 · Reply

QES Nov. 14 at 3:06 PM

$GRI https://www.perplexity.ai/search/https-s3-amazonaws-com-sec-irp-YVdgpNKzSkGC7UsGLeoaXQ I added a question, of sorts, telling AI why I sold out. It's the last question in that series. I am sharing to give you possibly new ideas of what is going on here.

0 · Reply

AtlasOG Nov. 14 at 3:02 PM

$GRI needs to follow $ASBP, hopefully with the shutdown over they got whatever info was in limbo

0 · Reply

QES Nov. 14 at 2:38 PM

$GRI Too much uncertainty for me. IMO, they are delaying reporting because they think the data is not good enough, and have been selling shares to raise capital while the price is up. I could easily be wrong, but I am not going to run more risk and loss here. GL to all!

0 · Reply

Gators909 Nov. 14 at 2:28 PM

$GRI the writing is probably on the wall that they didn’t pair the financials with the topline

0 · Reply

Mahdinur Nov. 14 at 2:25 PM

$GRI Institution own less than 2% of float. Instution dont buy because of confidence , they buy because of diversification and you can see they own near nothing. If anyone wants to gamble (i don't) recommendation is choose appropriate position size and risk management according to how much you are willing to loose. I am not a gambler.

1 · Reply

NolAsrtormZ Nov. 14 at 2:22 PM

$GRI im gambling with the recent institutional adds.

0 · Reply

NolAsrtormZ Nov. 14 at 2:20 PM

$GRI +/_ a few 4 Turkey day

0 · Reply

NolAsrtormZ Nov. 14 at 2:20 PM

$GRI 10 more business days until end of November. Not 2 bad

1 · Reply

Market Cap	4.25M
Revenue (ttm)	0.00
Net Income (ttm)	-8.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	82,900
Avg Vol	1,474,482
Day's Range	N/A - N/A
Shares Out	2.52M
Stochastic %K	39%
Beta	-1.45
Analysts	Sell
Price Target	$22.50